Related Experiment Video
Updated: Mar 3, 2026
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
[Relation of MiR-34a Expression in Diffuse Large B Cell Lymphoma with Clinical Prognosis]
Yi-Ping Liu1, Hong Hu1, Fang Xu1
1Department of Hematology, Mianyang Central Hospital,Mianyang 621000, Sichuan Province,China.
Objective:
To investigate the expression of miR-34a in serum of DLBCL patients, and to analyze its correlation with the expression of BCL-2 protein and clinical prognosis.
Methods:
The clinical data of 65 DLBCL patients and 22 cases of lymphonode reactive hyperplasia (RH) were collected, the serum expressions of miR-34a and BCL-2 were detected by real-time fluorescence quantitative PCR, and the relationship of miR-34a and BCL-2 expression with clinical pathological features and prognosis was analyzed.
Results:
The miR-34a lowly expressed in DLBCL and the BCL-2 highly expressed in DLBCL, the miR-34a expression level correlated negatively with BCL-2 expression (P<0.01). The survival time of patients with high expression of miR-34a was significantly longer than that of patients with miR-34a low expression. Multivariate Cox regression analysis revealed that the expression of miR-34a (P<0.01) and BCL-2 (P<0.01) as well as clinical staging (P<0.01) were independent factors influencing the prognosis of patients with DLBCL.
Conclusion:
The low expression of miR-34a in DLBCL patients may be involved in the occurrence and development of diffuse large B cell lymphoma, the MiR-34a is correlated with prognosis of diffuse large B cell lymphoma.
